Most Read Articles
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.

About half of CVD patients could be eligible for PCSK9 inhibitors

10 Jan 2018

About half of patients with cardiovascular disease (CVD) may be eligible for proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor therapy and results from a study of a large Canadian population-based cohort show such therapy may prevent CV events, though with significant costs. [Ko DT, et al, AHA 2017, abstract 778]

Among 62,729 adult patients with CVD, 61 percent, or 2.6 percent of the general population, were eligible for PCSK9 inhibitors based on eligibility criteria of the FOURIER trial (ie, fasting LDL-cholesterol 70 mg/dL or non–HDL-cholesterol ≥100 mg/dL while on an optimized lipid-lowering regimen).

“Applying the FOURIER hazard ratio to our study, we found a reduction in primary outcome [CV death, MI, unstable angina, stroke or coronary revascularization] of about 1.3 percent with PCSK9 inhibitors, which is similar to results of the FOURIER study,” said lead researcher Dr Dennis Ko of the Institute for Clinical Evaluative Sciences in Toronto, Ontario, Canada. 

“This was associated with a high cost per event,” he added, noting that the anticipated absolute clinical benefit in their trial may be smaller than reported in other PCSK9 inhibitor trials because of low overall event rates.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.